Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Paracetamol formulation 4 Clear all

Conditions: Headache, Tension-Type
Interventions: Placebo, Experimental paracetamol + caffeine formulation, ibuprofen marketed formulation, Paracetamol marketed formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Pembroke Pines, Florida • Springfield, Massachusetts • Wellesley Hills, Massachusetts + 4 more

Conditions: Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
Interventions: iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab; Genetic · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more

Conditions: Analgesia
Interventions: Paracetamol, Paracetamol formulation 1, Paracetamol Formulation 2, Paracetamol formulation 3, Paracetamol formulation 4; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Pain, Nausea, Vomiting
Interventions: CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo, Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg); Drug
Lead sponsor: Joseph Hazelton; Industry
Eligibility: 18 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Nausea, Vomiting
Interventions: CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo; Drug
Lead sponsor: Charleston Laboratories, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acetaminophen Overdose
Interventions: Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Phoenix, Arizona • Loma Linda, California • Orange, California + 11 more

Conditions: Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions: Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil; Drug
Lead sponsor: University of Utah; Other
Eligibility: Up to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acetaminophen Toxicity
Interventions: First Treatment Period, Washout, Second Treatment Period; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 20 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Labor, Premature, Preterm Premature Rupture of the Membranes, Infection, Inflammation, Chorioamnionitis
Interventions: amniocentesis, N-acetylcysteine or placebo; Procedure · Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • Columbus, Ohio

Conditions: Disorder of Knee
Interventions: Oxycodone; Drug
Lead sponsor: International Clinical Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pain
Interventions: Paracetamol and Caffeine, Ibuprofen, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 365 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Glycogen Storage Disease Type III
Interventions: UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker; Biological · Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Search by objective public record fields.

Paracetamol With Caffeine to Treat Episodic Tension Type Headache

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing

N-acetylcysteine in Intra-amniotic Infection/Inflammation

Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery

Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults